Cingulate Inc.
CING•NASDAQ•Healthcare•Biotechnology

About Cingulate

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOShane Schaffer
Founded2012
IPO DateDecember 8, 2021
Employees13
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.cingulate.com
Phone913 942 2300
Address
1901 West 47th Place Kansas City, Kansas 66205 United States

Corporate Identifiers

CIK0001862150
CUSIP17248W105
ISINUS17248W3034
EIN86-3825535
SIC2834

Leadership Team & Key Executives

Dr. Shane J. Schaffer Pharm.D.
Co-Founder, Chief Executive Officer and Director
Jennifer L. Callahan CPA
SVice President, Chief Financial Officer and Secretary
Dr. Raul R. Silva M.D.
Co-Founder, Executive Vice President and Chief Science Officer
Dr. Matthew N. Brams M.D.
Co-Founder, Executive Vice President and Chief Medical Officer
Thomas Dalton
Vice President of Investor and Public Relations
Nilay Patel J.D.
Chief Legal Officer
Downey Bryan Wade
Chief Commercial Officer